Login Register
English
0

Cart

$ 0

BRAF35 Polyclonal Antibody

BRAF35 Polyclonal Antibody

Views(51) Publications(0) Catalog no(ABP50787)
Datasheet Print Share Email Share
  • Specification
  • FAQ
  • Publications(0)
  • Comments(0)

Specification

Product name BRAF35 Polyclonal Antibody
Immunogen Synthesized peptide derived from the N-terminal region of human BRAF35 at AA range: 10-90
Host Rabbit
Reactivity Human
Applications ELISA, IF, IHC-P, WB
Applications notes Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), IHC-P (1:100-1:300), IF (1:200-1:1000), ELISA (1:20000). Not yet tested in other applications.
Clonality Polyclonal
Preparation method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen
Alternative HMG20B; BRAF35; HMGX2; HMGXB2; SMARCE1R; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related; SMARCE1-related protein; BRCA2-associated factor 35; HMG box-containing protein 20B; HMG domain-

Product Properties

Formulation Liquid solution
Concentration 1 mg/ml
Storage buffer PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Storage instructions Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Shipping Gel pack with blue ice.
Precautions The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Additional Information

Background The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.
Gene ID 10362
Alternative HMG20B; BRAF35; HMGX2; HMGXB2; SMARCE1R; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related; SMARCE1-related protein; BRCA2-associated factor 35; HMG box-containing protein 20B; HMG domain-
Others BRAF35 Polyclonal Antibody detects endogenous levels of BRAF35 protein.
Accession Q9P0W2
Observed Band(KD) 36

Image & description

Fig.1. Western Blot analysis of various cells using BRAF35 Polyclonal Antibody diluted at 1:2000.

Fig.1. Western Blot analysis of various cells using BRAF35 Polyclonal Antibody diluted at 1:2000.

Fig.2. Western Blot analysis of AD293 cells using BRAF35 Polyclonal Antibody diluted at 1:2000.

Fig.2. Western Blot analysis of AD293 cells using BRAF35 Polyclonal Antibody diluted at 1:2000.

This product has been cited in0publications

Reviews

There are no reviews yet.

Be the first to review “BRAF35 Polyclonal Antibody”